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doi:10.1016/j.jfma.2011.02.002Background/Purpose: Surgical resection for hepatocellular carcinoma (HCC) is regarded as
a curable treatment; however, the postoperative recurrence still poses a challenge to
surgeons. The effect of surgical margin on long-term outcome is still controversial, although
it has been considered as the treatment-related risk factor for recurrence. A precise assess-
ment of the effects of surgical margin on clinical outcome is required to clarify the issue.
Methods: A retrospective study was conducted on 407 patients with microscopically complete
resection of HCC; they were divided into three groups with surgical margin negative by
1e5 mm (Group A, n Z 156), 6e10 mm (Group B, n Z 109), and wider than 10 mm (Group
C, n Z 142). The groups were compared for clinicopathologic characteristics, perioperative
features, postoperative recurrence, and long-term outcome.
Results: The median follow-up time for all patients was 72.97 months. Recurrence rates were
similar among these groups. There was no significant difference in the overall 1-, 3-, and 5-year
actual survival rates for the groups on the log-rank test (p Z 0.073). After controlling the
independent risks for disease-free survival, there was also no significant difference in the
1-, 3-, and 5-year disease-free survival rates for the groups (p Z 0.354). The patients with
wider surgical margin had worse perioperative outcomes; more patients in this group needed
blood transfusion (p < 0.001) and more patients suffered from postoperative complications
(p Z 0.020). They also had higher in-hospital mortality rate than that of other groups
(1.41% vs. 0.64%).stitute of Healthcare Administration Kaohsiung Medical University, 100, Shih-Chuan 1st Road, San Ming
(H.-C. Chiu).
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Effect of surgical margin on hepatoma 161Conclusion: No superiority was seen in patients with wider surgical margin in either periopera-
tive features or long-term outcome.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatic resection is nowa safe procedure and represents the
only potentially curative option for hepatocellular carci-
noma (HCC), with a 5-year survival rate of 31.83e59%;1,2
however, the long-term survival is still unsatisfactory
because of high recurrent rate after hepatic resection.
Plenty of risk factors for HCC recurrence after surgery
have been studied. Margin status is an additional factor that
has been examined for its effect on disease-free survival
(DFS) and overall survival (OS) after surgery; however, its
clinical significance remains controversial. Shi et al3
demonstrated that the 1-, 2-, 3-, and 5-year OS rates for
the widemargin group were significantly better than that for
the narrow margin group, and indicated that, for macro-
scopically solitary HCC, a resection margin aiming grossly at
2 cm decreased postoperative recurrence rate efficaciously
and safely, and improved survival outcomes when compared
with a gross resection margin aiming at 1 cm. Zhou et al4
reported that the required minimal length of resection
margin is 6mm to achieve 100%micrometastasis clearance in
the surrounding liver tissue of HCC, and should be>18.5 mm
to obtain 99% micrometastasis clearance in surrounding liver
tissue of HCC patients with macroscopic tumor thrombi or
macrosatellites. In patients with cirrhosis and a small HCC,
anatomic resection obtains better DFS than limited resection
without increasing the postoperative risk.5 On the other
hand, Matsue et al6 reported that limited resection with no
margin seems to be the best procedure for patients with
tumors close to the major hepatic vessels and with hepatic
functions that do not permit wide-margin resections. They
indicated that nomargin resection for HCC do not negatively
affect patient’s outcomes. In patients with severely
impaired liver function or with tumor close to these large
vascular structures, an adequate surgical margin may not be
feasible. Poon et al7 also pointed out that most intrahepatic
recurrences were considered to arise from intrahepatic
metastasis by means of venous dissemination, which a wide
resection could not prevent.
The contradictory results could be contributory to the
heterogeneity of these series, in terms of various parame-
ters such as tumor characteristics, activity of the under-
lying disease, degree of fibrosis of the noncancerous
parenchyma, and host factors.
In the viewpoint of liver surgeons, surgical margin is just
one of the risk factors in terms of recurrence; complete HCC
resectionandavoidanceofhepatic failurearewhat theywant
to achieve most. The objective of this work is to examine the
influence of surgical margin status on perioperative and long-
term outcomes in patients with resectable HCC.
Materials and methods
Between January 2000 and July 2007, 547 consecutive
patients with HCC, all of whom underwent liver resectionsat Kaohsiung Medical University Hospital and Yuan’s
Hospital, were recruited for this study. The inclusion
criterions for liver surgery were as follows: (1) ChildePugh
class (i.e., A or B status); (2) tumor, lymph node, metastasis
(TNM) classification stages (i.e., stages I, II, and III-a); (3)
patency of main portal and hepatic veins; (4) no presence
of an extrahepatic metastasis; (5) no obvious ascites; and
(6) the level of bilirubin <2.0 mg/dL. During surgery,
accurate intraoperative ultrasonography was performed to
detect previously undocumented lesion(s); if more intra-
hepatic nodules were found or there was identifiable
evidence of extrahepatic diffusion, liver resection was not
performed. Intraoperative ultrasonography was also used to
mark the line of parenchyma transaction on the liver
surface to obtain an optimal width of tumor-free margin
and avoid/circumvent the major hepatic veins on the
transaction plane.
Among the recruited cases, we excluded patients who
received or underwent the following treatments or condi-
tions: (1) previous history of liver resection (n Z 20); (2)
treatment(s) with microwave ablation (n Z 15) or radio-
frequency ablation (n Z 24) during surgery; (3) ruptured
HCC (nZ 16); (4) liver resection for recurrent HCC (nZ 2);
(5) surgical margins not recorded (n Z 29); (6) surgical
margins not free from HCC (n Z 10); and (7) lack of detail
medical records (n Z 24). Finally, 407 patients were
included in our empirical analysis.
Patients were classified according to the width of the
surgical margin, defined as the shortest distance from the
edge of the tumor to the line of transaction. By this defi-
nition, margin status was then divided into three
subgroups: Group A (nZ 156), negative by 1e5 mm; Group
B (nZ 109), 6d10 mm; and Group C (nZ 142), wider than
10 mm.
Patients’ clinical information was obtained from medical
charts, reviewed by junior attending physicians in two
hospital departments, using a constructed instrument. The
information comprised patients’ demographics, clinical
variables, histological grades, tumor staging, and peri-
operative features. The extent of surgical resection was
defined according to Couinaud’s classification system.
Tumors were graded as welldfrom moderately to poorly
differentiateddaccording to the World Health Organization
(WHO) classification of tumors of the digestive system.
Tumors were staged according to the American Joint
Committee on Cancer (AJCC) (TNM) classification system.
All patients (except the three patients who died peri-
operatively) underwent routine and regular follow-up care
at our outpatient department and were carefully monitored
for pathological recurrence based on serum levels of a-
fetoprotein each month and abdominal ultrasonography
once every 3 months. Abdominal contrast-computed
tomography (CT) scan or magnetic resonance imaging
(MRI) was conducted when a possible recurrent lesion was
found in ultrasonographic assessment or levels of serum a-
fetoprotein was increasing continuously.
162 K.-T. Lee et al.To make a comparison between clinicopathological
features and perioperative treatments, all values were
expressedasmeanswith theirassociated standarddeviations.
Student t test or one-way analysis of variance (ANOVA) was
used for continuous variables, and a Chi-square or Fisher’s
exact test was used for categorical variables. The prognostic
significance of various clinicopathological factors with
respect toOSandDFS rateswasexaminedviaanapplicationof
univariate and multivariate Cox regression analysis tech-
niques. TheKaplaneMeiermethodwas first tobeemployed to
understand the association between the three resection
groups, and “OS” and “DFS.” Multiple Cox regression models
were used to explore the association further, while adjusting
all other clinical parameters. A p value of <0.05 was consid-
ered statistically significant. Data analysis was performed
using SPSS software (version 12.0) for Windows XP.Results
Table 1 shows that there was no evidence of significant
difference among the three groups with regard to demo-
graphic and clinicopathologic factors. The patients in Group
A, however, received less advanced histological grading of
HCC than those of the other two groups (p < 0.001).
Table 2 presents the perioperative features for these
patients with various resection margins. Eighty out of 142
patients (56.33%) in Group C received extensive liver
resection for the treatment of HCC, which is significantly
higher than in case of Group A patients (p < 0.001). More
patients in Group C (66/142, 46.48%) needed blood trans-
fusion during operation; it is significantly higher than in
other two groups (p Z 0.020). Twenty-two of 142 patients
(15.49%) in Group C suffered from postoperative compli-
cations, which is statistically the highest among the three
groups (p Z 0.042). Three patients died within 30 days of
liver resection (a perioperative mortality rate of 0.74%):
two of them were encountered in Group C patients (1.41%)
and one (0.64%) in Group A patients.
In this study, out of total 407 patients with a median
follow-up period of 72.97 months, 220 (54.1%) developed
a recurrence. The median time to recurrence was 21.27
months (range, 0.53e67.23 months), with the majority of
patients (78/220, 35.5%) recurring within 1 year after liver
resection. The 1-, 3-, and 5-year DFS rates were 64.6%,
50.1%, and 45.9%, respectively.
The median survival was 60.23 months, and the overall
mortality rate was 37.84%. The 1-, 3-, and 5-year OS rates
were 86.7%, 70.8%, and 63.9% respectively. Patients with
different surgical margins in Groups A, B, and C had similar
overall recurrence rates (58.97%, 54.13%, and 48.59%,
respectively), although recurrent rate was slightly higher in
patients with surgical margin of 1e5 mm (Group A) than in
those with wider margins; however, this difference was not
significant (p Z 0.199). In the meanwhile, no significant
difference in OS (Group A, 57.73  3.63 months; Group B,
55.35  4.12 months; and Group C, 62.58  3.48 months)
and disease-free period (Group A, 29.35  2.76 months;
Group B, 35.65  3.46 months; and Group C, 45.74  3.64
months) was found in patients with various surgical
margins, regardless of the width of the margins (pZ 0.370
and 0.073, respectively).To evaluate the possibility of HCC recurrence within
2 years (so-called early recurrence), we found that 186
(45.7%) of 407 patients had early HCC recurrence; the
median time for early recurrence was 5.88 months. For the
subgroups, 77 (49%) patients in Group A, 51 (47%) patients
in Group B, and 58 (41%) patients in Group C were found to
have early HCC recurrence. The difference is not statisti-
cally significant (p Z 0.385). The surgical margin is not
considered as a risk factor ever for the early HCC
recurrence.
Table 3 showed that patient in various groups had similar
patterns of HCC recurrence. It revealed that 87e89% of HCC
recurrence occurred in intrahepatic parenchyma. No
recurrence at surgical stump was found in any group. Most
of intrahepatic recurrence (61.7e70.4%) was found at
contralateral lobe of primary HCC.
Tables 4 and 5 dispatched the predicted models for DFS
and OS after hepatic resection, respectively. Multivariate
Cox regression analysis was performed for these significant
factors found in univariate analysis. Results of multivariate
Cox regression analysis showed that lower levels of serum
albumin, minor liver resection, and narrow surgical margin
adversely influenced DFS after liver resection (p < 0.05)
(Table 4). On the other hand, prognostic factors for OS of
HCC patients after hepatic resection were also analyzed.
The results revealed that minor liver resection, post-
operative complications, tumor numbers, HCC recurrence,
lower levels of serum albumin, and portal vein invasion all
significantly affected OS (p < 0.05) (Table 5).
The KaplaneMeier method revealed both DFS and OS
models among the three groups. The overall 1-, 3-, and 5-
year DFS rates were, respectively, 61.5%, 32.4%, and 22.1%
in Group A; 61.%, 44.9%, and 32.4% in Group B; and 64.5%,
49%, and 40.4% in Group C. Group C had higher DFS rate
than Group A, and the difference was statistically signifi-
cant (Group A vs. Group C, p Z 0.020) (Fig. 1A). However,
after controlling the independent risk factors for DFS, Cox
regression model showed that there was no significant
difference in no recurrence (Group A vs. Group B, pZ 0.364;
Group A vs. Group C, p Z 0.062) (Fig. 1B).
The overall 1-, 3-, and 5-year actual survival rates were,
respectively, 88.4%, 63.2%, and 44.1% in Group A; 81.1%,
60.4%, and 47.3% in Group B; and 87.5%, 69%, and 54.4% in
Group C. There was no significant difference among the
three groups, (Group A vs. Group B, pZ 0.717; Group A vs.
Group C, p Z 0.533; (Fig. 2A). After controlling the inde-
pendent risk factors for OS rate, multiple Cox regression
models demonstrated that still no significant difference
existed between groups (Group A vs. Group B, p Z 0.755;
Group A vs. Group C, p Z 0.242) (Fig. 2B). The results in
multiple Cox regression model estimates revealed that
there was no statistically significant difference between OS
and DFS. Improved survival was seen in HCC patients with
free surgical margins of liver resection, regardless of the
width of the margins (all p > 0.05).Discussion
Surgical resection is considered to be a curable treatment
for HCC, which is eligible for surgery; however, the post-
operative recurrence still poses a challenge to liver
Table 1 Demographic and clinicopathologic factors for HCC patients with various resection margins.
Variable Total cases N (%)/Mean(SD) Group P value
A(n Z 156) (1 w 5 mm) B(n Z 109) (6 w 10 mm) C(n Z 142) (>10 mm)
Age (year) 57.81 12.01 58.26 12.79 57.00 10.29 57.94 12.40 0.694
&65 290 71.25 110 70.51 85 77.98 95 66.90 0.152
>65 117 28.75 46 29.49 24 22.02 47 33.10
Gender Male 308 75.68 112 71.79 86 78.90 110 77.46 0.343
Female 99 24.32 44 28.21 23 21.10 32 22.54
Hepatitis status NBNC* 47 11.55 20 12.82 11 10.09 16 11.27 0.662
HBV 204 50.12 74 47.44 58 53.21 72 50.70
HCV 124 30.47 45 28.85 34 31.19 45 31.69
HBCV 32 7.86 17 10.90 6 5.50 9 6.34
ICGR15 (%) &15 109 26.78 35 32.11 30 38.96 44 39.64 0.456
>15 188 46.19 74 67.89 47 61.04 67 60.36
Liver cirrhosis No 130 31.94 50 32.05 32 29.36 48 33.80 0.755
Yes 277 68.06 106 67.95 77 70.64 94 66.20
The American Society of
Anesthesiologists (ASA)
classification
1 102 25.06 28 17.95 33 30.28 41 28.87 0.067
2 210 51.60 83 53.21 56 51.38 71 50.00
3 95 23.34 45 28.85 20 18.35 30 21.13
Tumor number Single 280 68.80 108 70.59 71 65.14 101 71.13 0.541
Multiple 124 30.07 45 29.41 38 34.86 41 28.87
Tumor size (cm) 4.15 2.89 4.03 3.10 3.90 2.59 4.47 2.87 0.241
TNM stage 1 222 54.55 89 60.69 61 56.48 72 52.17 0.318
2 132 32.43 41 28.08 40 37.04 51 36.96
3 38 9.34 16 10.96 7 6.48 15 10.87
Histological grading Well 90 22.78 40 27.40 26 23.85 24 17.14
Moderate 244 61.77 71 48.63 72 66.06 101 72.14 0.001
Poor 41 10.38 24 16.44 9 8.26 8 5.71
Portal vein invasion Unknown 20 5.06 11 7.53 2 1.83 7 5.00
No 320 78.62 125 80.13 92 84.40 103 72.54 0.064
Yes 87 21.38 31 19.87 17 15.60 39 27.46
* NBNC: not infected by neither Hepatitis B nor hepatitis C; HBV; Hepatitis B; HCV; Hepatitis C.
HBCV: infected both by hepatitis B and hepatitis C.
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Table 2 Perioperative features for HCC patients with various resection margins.
Variables Total cases N (%)/
Mean(SD)
Group P value
A(n Z 156) (1 w 5 mm) B(n Z 109) (6 w 10mm) C(n Z 142) (>10mm)
Resection margin (cm) 1.16 1.17 0.24 0.21 0.93 0.13 2.35 1.22 <0.001
Extent of resection Wedge and partial
resection
102 25.06 53 33.97 37 33.94 12 8.45 <0.001
1 segmentectomy 143 35.14 50 32.05 43 39.45 50 35.21
2 segmentectomy 100 24.57 32 20.51 22 20.18 46 32.39
S3 segmentectomy 62 15.23 21 13.46 7 6.42 34 23.94
Surgical procedure Laparoscopic 79 19.41 30 19.23 28 25.69 21 14.79 0.096
Open 328 80.59 126 80.77 81 74.31 121 85.21
Operation time (min) 193.19 177.83 212.89 271.91 178.49 76.35 183.12 72.25 0.214
Blood loss (ml) 782.79 917.74 753.78 871.41 700.19 964.79 877.85 928.2 0.278
Blood transfusion No 244 59.95 91 58.33 77 70.64 76 53.52 0.020
Yes 163 40.05 65 41.67 32 29.36 66 46.48
Amount of blood transfusion (ml) 353.93 603.84 364.90 625.95 247.71 478.10 423.42 656.03 0.070
Postoperative complication No 362 88.94 146 93.59 96 88.07 120 84.51 0.042
Yes 45 11.06 10 6.41 13 11.93 22 15.49
Hospital stay (day)(median) 13 14 13 13.5 0.977
Perioperative mortality No 404 99.26 155 99.36 109 100.00 140 98.59 0.427
Yes 3 0.74 1 0.64 0 0.00 2 1.41
Alpha-fetoprotein (AFP) (ng/dl) &400 327 81.55 128 83.12 87 80.56 112 80.58 0.815
>400 74 18.45 26 16.88 21 19.44 27 19.42
Aspartate aminotransferase
(AST) (IU/L)
&80 316 77.64 125 80.13 85 77.98 106 74.65 0.523
>80 91 22.36 31 19.87 24 22.02 36 25.35
Bilirubin (mg/dl) &1.0 305 75.31 115 74.19 81 75.00 109 76.76 0.874
>1.0 100 24.69 40 25.81 27 25.00 33 23.24
Albumin (gm/dl) >3.5 310 77.11 117 76.47 80 74.07 113 80.14 0.513
&3.5 92 22.89 36 23.53 28 25.93 28 19.86
Platelet (103/ml) >150 205 50.49 74 47.74 53 48.62 78 54.93 0.419
&150 201 49.51 81 52.26 56 51.38 64 45.07
Child-Pugh classification A 395 97.05 150 96.15 104 95.41 141 99.30 0.138
B 12 2.95 6 3.85 5 4.59 1 0.70
HCC Z hepatocellular carcinoma.
AFP Z alpha-fetoprotein.
AST Z Aspartate aminotransferase.
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Table 3 Patterns of recurrence stratified by surgical margin status.
Mode of recurrence Patients with recurrence
Group A (%) Group B (%) Group C (%)
No. of recurrence 92 59 69
Intrahepatic recurrence 81 (89.0) 52 (88.6) 60 (87.0)
Solitary lesion 63 (67.9) 36 (60.0) 34 (56.7)
Multiple lesion 29 (32.1) 24 (40.0) 26 (42.3)
Ipsilateral lobe 19 (21.0) 16 (25.7) 17 (28.5)
Contralateral lobe 65 (70.4) 37 (63.0) 37 (61.7)
Bilateral lobe 8 (8.4) 7 (11.3 6 (10.0)
Recurrence at surgical stump 0 0 0
Extrahepatic recurrence 10 (11.0) 7 (11.3) 9 (13.0)
Effect of surgical margin on hepatoma 165surgeons. Using a wide surgical margin to improve the
surgical outcome is advocated by many investigators,3,5,7,8
but the clinical significance still remains controversial.
The present study demonstrated that a liver resection with
wider surgical margin (10 mm) was not a significant factorTable 4 Prognostic factors for DFS of HCC patients after hepat
Variable N
HR
Anti-HCV No 251 1.346
Yes 156
Extent of resection Wedge and partial
resection
102
1 segmentectomy 143 0.53
2 segmentectomy 100 0.69
3 segmentectomy 62 0.85
Surgical procedure Laparoscopic 79 0.691
Open 328
Resection margins (mm) 1e5 156
6e10 109 0.85
>10 142 0.69
Complication No 362 1.507
Yes 45
Liver cirrhosis No 130 1.477
Yes 277
Tumor number Single 280 1.792
Multiple 124
AJCC TNM 1 222
2 132 1.82
3 38 2.48
ASA classification 1 102
2 210 0.73
3 95 0.88
ASP 80 316 1.39
>80 91
Albumin >3.5 310 1.75
3.5 92
Platelet >150 205 1.48
150 201
Portal vein invasion No 320 1.71
Yes 87
AJCC Z American Joint Committee on Cancer; CI Z confidence i
HCC Z hepatocellular carcinoma; HCV Z hepatitis C virus; TNM Z tassociated with a better DFS and OS for resectable HCC.
Matsue et al6 demonstrated similar results that no margin
seems to be the best procedure for patients with tumor
close to the major hepatic vessels and with hepatic func-
tions that do not permit wide-margin resections. The widthic resection.
Univariate analysis Multivariate analysis
95% CI p HR 95% CI p
1.030e1.761 0.030 1.05 0.77e1.44 0.735
0.38e0.75 0.000 0.61 0.40e0.95 0.027
0.48e0.99 0.045 0.85 0.53e1.37 0.513
0.56e1.29 0.445 0.95 0.54e1.69 0.868
0.505e0.946 0.021 0.84 0.55e1.28 0.420
0.075
0.61e1.18 0.320 0.88 0.62e1.24 0.457
0.51e0.95 0.023 0.63 0.44e0.89 0.010
1.000e2.271 0.050 1.38 0.87e2.19 0.165
1.078e1.942 0.014 1.07 0.75e1.54 0.694
1.356e2.369 <0.001 1.40 0.91e2.15 0.125
1.36e2.44 <0.001 1.19 0.73e1.92 0.485
1.60e3.85 <0.001 1.73 0.86e3.46 0.124
0.127
0.54e1.00 0.047 0.78 0.56e1.10 0.157
0.60e1.29 0.502 0.77 0.50e1.20 0.253
1.03e1.90 0.034 1.41 0.98e2.01 0.061
1.29e2.38 <0.001 1.44 1.03e2.02 0.034
1.13e1.93 0.004 1.25 0.89e1.75 0.196
1.27e2.31 <0.001 0.45 0.91e2.30 0.120
nterval; DFS Z disease-free survival; HR Z hepatic resection;
umor, lymph node, metastasis.
Table 5 Prognostic factors for OS of HCC patients after hepatic resection.
Variable N Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
Anti-HCV No 251 1.47 1.07e2.01 0.018 1.29 0.88e1.87 0.189
Yes 156
Extent of resection Wedge and partial
resection
102
1 segmentectomy 143 0.57 0.38e0.86 0.007 0.49 0.30e0.79 0.003
2 segmentectomy 100 0.60 0.38e0.93 0.024 0.54 0.30e0.95 0.031
3 segmentectomy 62 1.13 0.72e1.78 0.604 0.77 0.38e1.54 0.452
Blood transfusion (mL) 1000 372 1.83 1.13e2.96 0.014 0.57 0.28e1.18 0.129
>1000 35
Complication No 362 3.11 2.11e4.57 <0.001 3.21 2.03e5.08 <0.001
Yes 45
Liver cirrhosis No 130 2.21 1.48e3.32 <0.001 1.46 0.87e2.45 0.154
Yes 277
Tumor number Single 280 2.57 1.87e3.54 <0.001 2.06 1.25e3.39 0.005
Multiple 124
Tumor size (cm) 5 307 1.45 1.02e2.05 0.037 1.10 0.65e1.86 0.715
>5 97
AJCC TNM 1 222 <0.001
2 132 2.22 1.54e3.22 <0.001 0.81 0.45e1.46 0.480
3 38 4.90 3.10e7.75 <0.001 1.84 0.91e3.69 0.088
ASA classification 1 102 0.013
2 210 0.64 0.44e0.91 0.014 0.97 0.63e1.50 0.906
3 95 1.07 0.69e1.65 0.777 1.24 0.72e2.14 0.439
HCC recurrence No 187 2.68 1.83e3.92 <0.001 2.14 1.40e3.27 <0.001
Yes 220
ASP (IU/L) 80 316 1.55 1.10e2.19 0.012 1.23 0.80e1.88 0.337
>80 91
Bilirubin (mg/dL) 1.0 305 1.84 1.30e2.60 0.001 1.22 0.79e1.89 0.372
>1.0 100
Albumin (g/dL) >3.5 310 2.78 1.99e3.87 <0.001 1.78 1.16e2.73 0.009
3.5 92
Platelet (103/mL) >150 205 1.46 1.06e2.01 0.022 1.02 0.66e1.57 0.934
150 201
ChildePugh classification A 395 4.59 2.33e9.06 <0.001 2.01 0.84e4.82 0.118
B 12
Histological grading Well 90
Moderate 244 1.05 0.71e1.54 0.818 1.15 0.73e1.84 0.545
Poor 41 1.92 1.13e3.26 0.016 1.80 0.95e3.44 0.073
Unknown 20 0.45 0.19e1.08 0.073 0.41 0.13e1.22 0.109
Portal vein invasion No 320 2.39 1.71e3.35 <0.001 1.70 1.04e2.79 0.036
Yes 87
AJCC Z American Joint Committee on Cancer; CI Z confidence interval; HR Z hepatic resection; HCC Z hepatocellular carcinoma;
HCV Z hepatitis C virus; OS Z overall survival; TNM Z tumor, lymph node, metastasis.
166 K.-T. Lee et al.of the resection margin did not influence the postoperative
recurrence rates after hepatectomy for HCC.7 The only
effect of a wide surgical margin appeared to be the
prevention of stump recurrence, which may be considered
as a true local recurrence related to inadequate resection.
The finding is not in accordance with the report from Wu
et al,9 which demonstrated that better outcome was found
for early recurrence rate of HCC patients. The contradic-
tion might be attributed to the heterogeneity of tumor
characteristics, such as venous invasion (Wu’s 71.5% vs.
author’s 21.4%), and grade III histologic grading (Wu’s 23.4%vs. author’s 10.38%). By replacing 1-year cutoff with 2-year
cutoff in the definition of early recurrence rate, which was
adopted by Wu and associates, no statistical significance
was found (results are not shown in this paper).
HCC recurrence is characterized by two unique histo-
logical features: intrahepatic spread and multicentric
recurrence. Intrahepatic metastasis occurred mainly by
means of portal venous spread and could occur anywhere in
the liver remnant. In this study, patients in three groups
have similar overall recurrent rates (58.97% vs. 54.13% vs.
48.5%, respectively, pZ 0.199), and almost all recurrences
A B
Figure 1 (A) KaplaneMeier estimates of DFS of HCC patients with various resection margins. There was no significant difference
in no recurrence among the three groups on the log-rank test (p Z 0.073) (Group A vs. Group B, p Z 0.281; Group A vs. Group C,
p Z 0.020). (B) After controlling the independent risk factors for DFS, there was no significant difference in no recurrence on the
Cox regression (p Z 0.171) (Group A vs. Group B, p Z 0.364; Group A vs. Group C, p Z 0.062). DFS Z disease-free survival;
HCC Z hepatocellular carcinoma.
Effect of surgical margin on hepatoma 167were found in the liver remnant. More than half of the
recurrences were found in the contralateral lobe, indi-
cating that recurrence is influenced by the width of surgical
margin, and no recurrence was found at surgical stump,
indicating that recurrence may originate from either
intrahepatic metastasis or multicentric carcinogenesis;BA
Figure 2 (A) KaplaneMeier estimates of OS of HCC patients with v
OS rate among the three groups (pZ 0.370) (Group A vs. Group B, p
the independent risk factors for OS, there was no significant differ
p Z 0.755; Group A vs. Group C, p Z 0.242). HCC Z hepatocellulthus, a wider resection margin is considered to have limited
value. Poon et al7 demonstrated that there was no signifi-
cant difference between the patients with wider and
narrow surgical margins in terms of intrahepatic recur-
rence. Most of the recurrent tumors were developed at
a distal segment or multiple segments in both groups. Poonarious resection margins. There was no significant difference in
Z 0.074; Group A vs. Group C, pZ 0.219). (B) After controlling
ence on the Cox regression (p Z 0.354) (Group A vs. Group B,
ar carcinoma; OS Z overall survival.
168 K.-T. Lee et al.et al10 advocated that the propensity of HCC to disseminate
by means of portal venous system means that intrahepatic
metastasis is likely to be present beyond 1 or 2 cm in most
patients. Intrahepatic recurrence may also arise from
multicentric carcinogenesis in the liver remnant, which also
cannot be prevented by a wide surgical margin.
The risk factors for postoperative recurrence after
resection of HCC have been studied extensively. They can
be categorized into tumor, host, and surgical factors.10 For
the tumor factors, it is widely accepted that vascular
invasion, satellite nodules, and tumor size are important
mechanisms for intrahepatic metastasis. The TMN staging
also provides an accurate prognostic classification of the
long-term survival after resection of HCC.
Several tumor biologic factors such as DNA ploidy,11
proliferating cell nuclear antigen index,12 telomerase,13
androgen receptor,14 mutation of p53 gene,15 and angio-
genesis16 are related to the growth and invasiveness of
HCC. Metastatic tumor antigen 117,18 is closely associated
with microvascular invasion and poor survival in HCC
patients. Micro-RNA (miRNA) may provide a similar profiling
method to assist in identifying patients with HCC who are
likely to develop a metastatic recurrence.19,20 Ezrin over-
expression increased the risk of early recurrence.21 Akt
phosphorylation is a risk factor for early disease recurrence
and poor prognosis in HCC.22 Increased CD4 (þ) CD25 (þ)
Fox P3(þ) Treg may impair the effect or function of CD8(þ)
T cells, promoting disease progression.23
For the host factors, HCC patients with hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection were attributed
to a higher risk of HCC recurrence. Chuma et al24 demon-
strated that high serum HPV DNA levels and absence of
antiviral therapy were independent risk factors for HCC
recurrence. Patients with higher viral loads tended to have
higher Ishak inflammatory and fibrosis scores than those
with lower loads and associated with late recurrence.9
Interferon therapy can improve postoperative outcomes in
patients with HCV-related HCC by suppressing recurrence
and preventing progress of cirrhosis, especially when
interferon therapy has controlled their active hepatitis.25
Due to the availability of data set, the above parameters
were not included in the present paper. Therefore, the
association could not be identified. To have a complete and
comprehensive predictors of HCC patient survival research,
the above parameters is suggested to be collected at
prospective study design study.
The main surgical factors for HCC recurrence, such as
the extent of resection, surgical margin, and perioperative
transfusion, have also been examined widely. Although
some investigators advocate that anatomic resection
independently improves long-term survival26 and achieves
better DFS27 in HCC patients, Kaibori et al28 pointed out
that anatomic resection did not provide any significant
benefit in patients with HCV-associated HCC. Kuniya et al29
also demonstrated that no superiority was seen in survival
when HCC was treated by anatomic resection. Maintaining
adequate liver function regardless of whether the resection
is anatomic or not may be of greater importance. The
severity of cirrhosis and tumor characteristics depicts long-
term survival rather than the type of resection in HCC.
Blood transfusion is one of the independent risk factors
that affect the DFS and OS in a multivariate analysis.30e33Katz et al34 found that the magnitude of estimated blood
loss during HCC resection is related to biologic character-
istics of the tumor as well as to the extent of surgery.
Increased intraoperative blood loss during HCC resection is
an independent prognostic factor for HCC recurrence and
death. Transfusion of blood product is associated with
increased recurrence rate and worse survival after HCC
surgery.
Postoperative complications can affect overall long-
term survival after resection of HCC. Chok et al35 using
Cox proportional hazard model analysis revealed that the
presence of postoperative complications can affect overall
long-term survival after resection of HCC. Schiffiman et al36
also demonstrated that treatment complication was one of
the significant adverse factors for HCC resection.
In this study, more patients in Group C received exten-
sive surgical resection compared to the other two groups
(p < 0.001), to get a wider surgical margin. However, the
patients in Group C have encountered heavy blood loss
and needed blood transfusion (p Z 0.020) during liver
resection. Excessive blood loss and blood transfusion are
associated with a significantly higher postoperative
complication rate in Group C patients (p Z 0.042). The
finding is in accordance with the report from Chok et al.35
Two out of 140 patients in Group C died within 30 days of
liver resection, indicating a perioperative mortality rate of
1.4%; it is much higher than that of patients in Group A
(0.64%) and Group B (0%), although it is not statistically
significant. Therefore, it is obvious that no superiority was
seen in patients with wider surgical margin in regard to
perioperative outcomes.
The prognostic factors for DFS or OS after HCC resection
have extensively been studied. Most authors37e40 empha-
sized the important role of vascular invasion in HCC
recurrence after surgery, although plenty of factors (such
as preoperative liver function including elevation alkaline
phosphatase value, elevated alanine transferase value,
lower serum albumin, ChildePugh status; tumor charac-
teristics including a-fetoprotein, tumor size, tumor
number, presence of daughter nodules, tumor stage, and
differentiation; and perioperative features including extent
of surgery, surgical margin, and blood transfusion) are still
regarded as independent risk factors for DFS and OS in
multivariate analysis. Therefore, HCC recurrence after liver
resection is associated with multiple factors, and not
a single factor of resection margin. In the current study, we
demonstrated that the patients in Group C had significantly
higher DFS rate when compared to patients in Group A
(p Z 0.02); however, it became insignificant (Group A vs.
Group C, p Z 0.062) after controlling the independent risk
factors. The information indicated that weak association
existed for wide resection margin and survival rate. On
the other hand, variables such as extent of resection and
albumin were consistently significantly associated with
both DFS and OS rates. This finding indicated that, in the
long-term follow-up, resection margin is not an important
risk factor for HCC recurrence as compared with others.
The present study identified that liver resection with
a wide surgical margin was not a significant factor associ-
ated better DFS and OS for resectable HCC. A wide surgical
margin for HCC is not an effective strategy for reducing the
risk of postoperative recurrence. Most of the recurrences
Effect of surgical margin on hepatoma 169were related to intrahepatic metastasis or multicentric
carcinogenesis, and hence could not be prevented by
a wide surgical margin. In patients with limited liver func-
tion reserve, preservation of liver parenchyma should take
priority over a wide surgical margin, and surgical margin
should not be overemphasized to impact the surgical long-
term outcome of HCC.References
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